AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson

Even after the novel coronavirus is contained, healthcare stocks will remain in focus. Good time to accumulate stocks with strong growth outlook.

3 Top Healthcare Stocks for a More Aware World

BioNTech SE

Emergent BioSolutions

Merck

Moderna

Pfizer

Globally, there are more than 100 vaccines under development — with nine of them in human clinical trials already, asserts equity analyst Sel Hardy, in CFRA Research's flagship newsletter, The Outlook.

9 Pharmaceutical Companies Racing For A COVID-19 Vaccine

The British drugmaker has already begun human trials of the vaccine developed by the University of Oxford, with a phase I trial in Britain due to end soon.

AstraZeneca COVID-19 vaccine likely to protect for a year, CEO says

Catalent

The contract manufacturer will be able to supply hundreds of millions of doses of AZD1222 starting in August.

Catalent to Mass-Produce a Coronavirus Vaccine for AstraZeneca and Oxford University

AstraZeneca's (AZN) supply deals will require it to produce 2 billion doses of the vaccine, if it is successfully developed.

AstraZeneca to Supply 400M Coronavirus Vaccine Doses in Europe

Inovio Pharmaceuticals

Some of the earliest novel coronavirus (COVID-19) vaccines to be approved are more likely to target prevention against developing severe symptoms from catching the virus, rather than the initial infection, multiple health experts told Bloomberg.

Early Coronavirus Vaccines Likely To Target Further Complications, Not Infection, Health Experts Say

Italy, Germany, the Netherlands and France have reportedly agreed to pay an initial 750 million euros ($843.2 million) for 300 million doses of AstraZeneca's potential vaccine against Covid-19.

Four European nations to pay $843 million for AstraZeneca's coronavirus vaccine

AstraZeneca plc (NYSE: AZN) on Saturday said it had reached an agreement with Europe's Inclusive Vaccines Alliance (IVA) to supply 400 million doses of its novel coronavirus (COVID-19) vaccines by the end of the year.

AstraZeneca Strikes Deal With Four EU Countries Over 400M Coronavirus Vaccine Doses

Emergent BioSolutions (EBS) inks a deal with AstraZeneca to provide its CDMO services for supporting the manufacturing of the latter's COVID-19 vaccine candidate, AZD1222.

Emergent (EBS) to Manufacture AstraZeneca's Coronavirus Vaccine

The agreement is valued at approximately $87 million.

Emergent BioSolutions Will Manufacture AstraZeneca's COVID-19 Vaccine Candidate

Even though Roche ( RHHBY ) was the pharma company that pumped the most money into R&D in 2019 - an astonishing $12.06 billion - AstraZeneca ( AZN ) recorded the greatest increase in spending at 21%.

AstraZeneca’s R&D Spending Spikes 21% to Industry Best in 2019

In an announcement on Tuesday, AstraZeneca (LON: AZN) revealed that the U.S. Biomedical Advanced Research and Development Authority (BARDA) funded £18.60 million to help the drug manufacturer ramp up production of its experimental COVID-19 vaccine.

AstraZeneca receives £18.60 million funding from U.S. BARDA

Britain's biggest pharmaceutical has expanded its agreements with two U.S. government agencies and Vanderbilt University.

AstraZeneca Boosts Its COVID-19 Research with More Help From the Public Sector

Gilead Sciences

Gilead (GILD) gains after report surfaces that AstraZeneca has shown interest in the former last month.

Gilead Up on Report of AstraZeneca's Interest in Merger

Biotech company Gilead gained FDA's nod for its coronavirus treatment. It also reportedly received takeover interest from pharmaceutical giant AstraZeneca.

Gilead Reportedly Receives AstraZeneca Interest — Is GILD Stock A Buy?

This reported deal would be massive. But it's not likely to move forward.

AstraZeneca's Acquisition of Gilead Would Create a COVID-19 Colossus -- but Don't Bet on Seeing It Happen

AstraZeneca And Gilead Sciences Merger Rumors - Something To Watch

The weekend was abuzz with rumors of U.K. pharma giant AstraZeneca plc's (NYSE: AZN) reported interest in U.S.

4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize

A merger between AstraZeneca and Gilead Sciences Inc  is unlikely due to significant political hurdles, Wall Street analysts said on Monday after a Bloomberg report that the British drugmaker last month had contacted its U.S. rival about a deal.

AstraZeneca, Gilead merger doubted by Wall Street analysts

The merger of AstraZeneca and Gilead Sciences would be the biggest pharma deal in history if it goes through.

AstraZeneca Explores Merger With COVID-Drug Developer Gilead: Report

Peer-reviewed data on AstraZeneca's (AZN) Calquence shows that it improves laboratory markers of inflammation and decreases oxygen requirements in most patients hospitalized due to COVID-19.

AstraZeneca's Calquence Shows Promise as Coronavirus Treatment

Britain's AstraZeneca has approached U.S. rival Gilead Sciences about a possible merger to form one the world's largest drug companies.

AstraZeneca contacted Gilead over potential megamerger

AstraZeneca is reportedly interested in scooping up coronavirus treatment maker Gilead Sciences, according to several reports that prodded GILD stock on Monday.
The post Gilead Sciences Pops On Rumored Takeover Interest From AstraZeneca appeared first on Investor's Business Daily.

Gilead Sciences Pops On Rumored Takeover Interest From AstraZeneca

AstraZeneca has approached Gilead Sciences about a massive merger that would combine two companies leading the pharmaceutical industry's battle against the coronavirus.

AstraZeneca eyes potential merger with Gilead Sciences

Shares of U.S. drugmaker Gilead Sciences Inc  rose over 5% in premarket trading on Monday after a report it had been approached by Britain's AstraZeneca  for a possible merger to form one of the world's largest drug companies.

News for AstraZeneca Stock (AZN)